我们遇到了敌人,他就是我们

Mark S. Schreiner, Barbara C. Engel
{"title":"我们遇到了敌人,他就是我们","authors":"Mark S. Schreiner, Barbara C. Engel","doi":"10.1080/21507716.2011.605420","DOIUrl":null,"url":null,"abstract":"Numerous authors have demonstrated that when multiple institutional review boards (IRBs) review the same protocol, the results are quite variable (Dilts et al. 2009; Dziak et al. 2005; Green et al. 2006; Greene et al. 2006; Helfand et al. 2009; Kimberly et al. 2006; Mansbach et al. 2007; McWilliams et al. 2003; Silverman et al. 2001; Stair et al. 2001; Stark et al. 2010). However, the federal regulations governing the conduct of human subjects research are gray, by either design or accident, and it is therefore to be expected that reasonable people with differing interpretations will reach disparate conclusions about whether or not a given study meets the criteria for approval (Sayers 2007). Klitzman (2011) provides anecdotal evidence that lends credence to another aspect of IRB variability long known to clinical investigators, namely, that there are differences between the IRBs within institutions. The Klitzman paper is fundamentally based on anecdotes. There is no reason why clinical research into IRB decision making shouldn’t be held to the same standards as those for other types of clinical research. As Halpern (2005) advocated recently, there is a need for evidence-based bioethics to inform decisions. From an epidemiologist’s perspective, large randomized clinical trials rank highest in strength of evidence, followed by smaller clinical trials, cohort studies, case-control studies, and then anecdotal evidence at the bottom. Depending on one’s perspective, meta-analyses combining the results of several trials would be at or near the top of the hierarchy of evidence. Even when a study has a high degree of internal validity, the results from a study may not be generalizable to one’s own situation, patient population, and institution. Given the low position within the hierarchy of evidence occupied by this current report, the results and conclusions reported by Klitzman should be viewed with caution and skepticism. If cause and effect are beyond the realm of the anecdotal study design, then why bother with this type of research? Not all research needs to involve confirmatory designs with formal hypothesis testing. Other exploratory designs are valuable when aimed at generating hypotheses and directions for future research. The power of this paper, then, is not in the amalgamation of the results into a","PeriodicalId":89316,"journal":{"name":"AJOB primary research","volume":"6 1","pages":"39 - 41"},"PeriodicalIF":0.0000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"94","resultStr":"{\"title\":\"We Have Met the Enemy and He Is Us\",\"authors\":\"Mark S. Schreiner, Barbara C. Engel\",\"doi\":\"10.1080/21507716.2011.605420\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Numerous authors have demonstrated that when multiple institutional review boards (IRBs) review the same protocol, the results are quite variable (Dilts et al. 2009; Dziak et al. 2005; Green et al. 2006; Greene et al. 2006; Helfand et al. 2009; Kimberly et al. 2006; Mansbach et al. 2007; McWilliams et al. 2003; Silverman et al. 2001; Stair et al. 2001; Stark et al. 2010). However, the federal regulations governing the conduct of human subjects research are gray, by either design or accident, and it is therefore to be expected that reasonable people with differing interpretations will reach disparate conclusions about whether or not a given study meets the criteria for approval (Sayers 2007). Klitzman (2011) provides anecdotal evidence that lends credence to another aspect of IRB variability long known to clinical investigators, namely, that there are differences between the IRBs within institutions. The Klitzman paper is fundamentally based on anecdotes. There is no reason why clinical research into IRB decision making shouldn’t be held to the same standards as those for other types of clinical research. As Halpern (2005) advocated recently, there is a need for evidence-based bioethics to inform decisions. From an epidemiologist’s perspective, large randomized clinical trials rank highest in strength of evidence, followed by smaller clinical trials, cohort studies, case-control studies, and then anecdotal evidence at the bottom. Depending on one’s perspective, meta-analyses combining the results of several trials would be at or near the top of the hierarchy of evidence. Even when a study has a high degree of internal validity, the results from a study may not be generalizable to one’s own situation, patient population, and institution. Given the low position within the hierarchy of evidence occupied by this current report, the results and conclusions reported by Klitzman should be viewed with caution and skepticism. If cause and effect are beyond the realm of the anecdotal study design, then why bother with this type of research? Not all research needs to involve confirmatory designs with formal hypothesis testing. Other exploratory designs are valuable when aimed at generating hypotheses and directions for future research. The power of this paper, then, is not in the amalgamation of the results into a\",\"PeriodicalId\":89316,\"journal\":{\"name\":\"AJOB primary research\",\"volume\":\"6 1\",\"pages\":\"39 - 41\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"94\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AJOB primary research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21507716.2011.605420\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJOB primary research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21507716.2011.605420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 94

摘要

许多作者已经证明,当多个机构审查委员会(irb)审查相同的方案时,结果是相当不同的(Dilts等人,2009;Dziak等人,2005;Green et al. 2006;Greene et al. 2006;Helfand et al. 2009;Kimberly et al. 2006;Mansbach et al. 2007;McWilliams et al. 2003;Silverman et al. 2001;Stair et al. 2001;Stark et al. 2010)。然而,管理人类受试者研究行为的联邦法规是灰色的,要么是故意的,要么是意外的,因此可以预期的是,理性的人对不同的解释会得出不同的结论,关于一个给定的研究是否符合批准的标准(Sayers 2007)。Klitzman(2011)提供了轶事证据,为临床研究者长期了解的IRB变异性的另一个方面提供了证据,即机构内IRB之间存在差异。克里茨曼的论文基本上是基于轶事。没有理由不将临床研究纳入伦理委员会的决策,与其他类型的临床研究采用相同的标准。正如Halpern(2005)最近提倡的那样,有必要以证据为基础的生物伦理学来为决策提供信息。从流行病学家的角度来看,大型随机临床试验的证据强度最高,其次是小型临床试验、队列研究、病例对照研究,最后是轶事证据。根据个人的观点,综合多项试验结果的荟萃分析将处于或接近证据等级的顶端。即使一项研究具有高度的内部效度,研究的结果也可能不能推广到自己的情况、患者群体和机构。鉴于本报告在证据层次中所占的地位较低,应该以谨慎和怀疑的态度看待Klitzman报告的结果和结论。如果因果关系超出了轶事研究设计的范围,那么为什么要进行这种类型的研究呢?并不是所有的研究都需要包含正式假设检验的验证性设计。其他探索性设计在为未来研究提供假设和方向时是有价值的。因此,本文的力量并不在于将结果合并成一个
本文章由计算机程序翻译,如有差异,请以英文原文为准。
We Have Met the Enemy and He Is Us
Numerous authors have demonstrated that when multiple institutional review boards (IRBs) review the same protocol, the results are quite variable (Dilts et al. 2009; Dziak et al. 2005; Green et al. 2006; Greene et al. 2006; Helfand et al. 2009; Kimberly et al. 2006; Mansbach et al. 2007; McWilliams et al. 2003; Silverman et al. 2001; Stair et al. 2001; Stark et al. 2010). However, the federal regulations governing the conduct of human subjects research are gray, by either design or accident, and it is therefore to be expected that reasonable people with differing interpretations will reach disparate conclusions about whether or not a given study meets the criteria for approval (Sayers 2007). Klitzman (2011) provides anecdotal evidence that lends credence to another aspect of IRB variability long known to clinical investigators, namely, that there are differences between the IRBs within institutions. The Klitzman paper is fundamentally based on anecdotes. There is no reason why clinical research into IRB decision making shouldn’t be held to the same standards as those for other types of clinical research. As Halpern (2005) advocated recently, there is a need for evidence-based bioethics to inform decisions. From an epidemiologist’s perspective, large randomized clinical trials rank highest in strength of evidence, followed by smaller clinical trials, cohort studies, case-control studies, and then anecdotal evidence at the bottom. Depending on one’s perspective, meta-analyses combining the results of several trials would be at or near the top of the hierarchy of evidence. Even when a study has a high degree of internal validity, the results from a study may not be generalizable to one’s own situation, patient population, and institution. Given the low position within the hierarchy of evidence occupied by this current report, the results and conclusions reported by Klitzman should be viewed with caution and skepticism. If cause and effect are beyond the realm of the anecdotal study design, then why bother with this type of research? Not all research needs to involve confirmatory designs with formal hypothesis testing. Other exploratory designs are valuable when aimed at generating hypotheses and directions for future research. The power of this paper, then, is not in the amalgamation of the results into a
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信